Loading…
VolitionRx Limited's subsidiary Belgian Volition SPRL closed on the acquisition of epigenetic reagent company Octamer GmbH for $725,000 (€650,000) in cash and stock. The deal secures supply of key components for Volition's Nu.Q cancer tests.